Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Reid Weyant Merryman, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Houot R, Merryman RW, Morschhauser F. Total immunotherapy for Hodgkin lymphoma. Lancet Haematol. 2020 09; 7(9):e629-e630. PMID: 32853579.
    Citations:    
  2. Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist. 2020 Jul 28. PMID: 32720734.
    Citations:    
  3. Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 May 19. PMID: 32430944.
    Citations:    
  4. Merryman RW, Houot R, Armand P, Jacobson C. Immune and Cell Therapy in Non-Hodgkin Lymphoma. Cancer J. 2020 May/Jun; 26(3):269-277. PMID: 32496460.
    Citations:    
  5. Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist. 2020 Jun; 25(6):e993-e997. PMID: 32275786.
    Citations:    
  6. Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867. PMID: 32126141.
    Citations:    
  7. Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126. PMID: 31917843.
    Citations:    
  8. Merryman RW, LaCasce A. Novel agents and immune invasion in Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):243-248. PMID: 31808827.
    Citations:    
  9. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32. PMID: 31723987.
    Citations:    
  10. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29. PMID: 30952672.
    Citations:    
  11. Merryman RW, LaCasce A. Reply to H.J.A. Adams et al. J Clin Oncol. 2018 Nov 10; 36(32):3274-3275. PMID: 30222482.
    Citations:    Fields:    
  12. Merryman RW, LaCasce AS. Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care. J Clin Oncol. 2018 07 10; 36(20):2009-2011. PMID: 29787359.
    Citations:    Fields:    
  13. Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018 07 05; 132(1):9-16. PMID: 29720488.
    Citations: 1     Fields:    
  14. Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017 Dec 12; 1(26):2643-2654. PMID: 29296917.
    Citations: 8     
  15. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 07 13; 130(2):221-228. PMID: 28468799.
    Citations: 17     Fields:    Translation:Humans
  16. Merryman RW, Armand P. Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. Curr Hematol Malig Rep. 2017 02; 12(1):44-50. PMID: 28155012.
    Citations:    Fields:    Translation:Humans
  17. Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, François S, Stamatoullas-Bastard A, Rohrlich PS, Labussière Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388. PMID: 28073785.
    Citations: 19     Fields:    Translation:Humans
  18. Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31. PMID: 28034071.
    Citations: 4     Fields:    Translation:Humans
  19. Merryman R, Stevenson KE, Gostic WJ, Neuberg D, O'Brien J, Sallan SE, Silverman LB. Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Nov; 59(5):925-7. PMID: 22532399.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  20. Mou D, Sarma A, Sethi R, Merryman R. The state of health policy education in U.S. medical schools. N Engl J Med. 2011 Mar 10; 364(10):e19. PMID: 21345091.
    Citations: 6     Fields:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Merryman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (55)
Explore
_
Co-Authors (36)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.